SEARCH:   Advanced

Blood, 3 September 2009, Vol. 114, No. 10, pp. 2044-2050. Prepublished online as a Blood First Edition Paper on June 24, 2009; DOI 10.1182/blood-2009-04-214346. This Article Full Text Full Text (PDF) Supplemental Tables All Versions of this Article: blood-2009-04-214346v1 114/10/2044    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via CrossRef Google Scholar Articles by Abrisqueta, P. Articles by Montserrat, E. PubMed PubMed Citation Articles by Abrisqueta, P. Articles by Montserrat, E. Related Collections Lymphoid Neoplasia Clinical Trials and Observations Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  CLINICAL TRIALS AND OBSERVATIONS Improving survival in patients with chronic lymphocytic leukemia (1980-2008): the Hospital Clínic of Barcelona experience Pau Abrisqueta1, Arturo Pereira2, Ciril Rozman3, Marta Aymerich4, Eva Giné1, Carol Moreno1, Ana Muntañola1, María Rozman4, Neus Villamor4, Kate Hodgson1, Elías Campo4, Francesc Bosch1, and Emili Montserrat1 1 Department of Hematology, Institute of Hematology and Oncology, 2 Hemotherapy and Blood Bank, 3 Hospital Clínic, and 4 Hematopathology Unit, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain Whether advances in treatment are prolonging survival of patients with chronic lymphocytic leukemia (CLL) is unclear. We analyzed presentation patterns and survival over time in 929 patients followed from 1980 to 2008 at the Hospital Clinic of Barcelona. The 5- and 10-year relative survival (adjusted for the expected survival in the general population) was estimated in patients seen in 2 periods of time: 1980-1994 (n = 451) and 1995-2004 (n = 365). We found that CLL shortens life expectancy in all age groups independently of clinical features at diagnosis. Nevertheless, survival is improving, particularly in some groups of patients. Thus, relative survival was significantly higher in the 1995-2004 cohort than in the 1980-1994 group both at 5 years (incidence rate ratio [IRR] = 0.46; P = .004) and 10 years (IRR = 0.65; P = .007) from diagnosis. The improved survival was largely due to a decrease in CLL-attributable mortality in patients younger than 70 years in Binet stage B or C at diagnosis (IRR = 0.40; P = .001 at 5 years; IRR = 0.33; P < .001 at 10 years). These results suggest that newer treatments are changing the prognosis of CLL, particularly in younger patients with advanced disease, whereas no improvement is yet observed in older subjects or those with lower-risk disease. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

	Copyright © 2009 by American Society of Hematology         Online ISSN: 1528-0020